Reviewing MedAvail (NASDAQ:MDVL) and China Dasheng Biotechnology (OTCMKTS:CDBT)

MedAvail (NASDAQ:MDVL) and China Dasheng Biotechnology (OTCMKTS:CDBT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings for MedAvail and China Dasheng Biotechnology, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MedAvail 0 1 1 0 2.50
China Dasheng Biotechnology 0 0 0 0 N/A

MedAvail presently has a consensus target price of $8.75, indicating a potential upside of 165.96%. Given MedAvail’s higher possible upside, research analysts plainly believe MedAvail is more favorable than China Dasheng Biotechnology.

Volatility & Risk

MedAvail has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, China Dasheng Biotechnology has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500.

Profitability

This table compares MedAvail and China Dasheng Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MedAvail -259.56% -77.27% -62.84%
China Dasheng Biotechnology N/A N/A N/A

Valuation and Earnings

This table compares MedAvail and China Dasheng Biotechnology’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MedAvail $13.97 million 7.71 -$26.81 million ($3.80) -0.87
China Dasheng Biotechnology N/A N/A N/A N/A N/A

China Dasheng Biotechnology has lower revenue, but higher earnings than MedAvail.

Insider & Institutional Ownership

86.8% of MedAvail shares are held by institutional investors. 3.7% of MedAvail shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MedAvail beats China Dasheng Biotechnology on 5 of the 9 factors compared between the two stocks.

MedAvail Company Profile

MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company was founded on April 11, 2007 and is headquartered in Mississauga, Canada.

China Dasheng Biotechnology Company Profile

China Dasheng Biotechnology Co. engages in the development, manufacture and sale of bacteria based products, which are used as additives for livestock feed and crop cultivation. It operates through the following business segments: Agriculture Related Additives for Livestock Feed and Crop Cultivation. The company was founded on January 12, 2007 and is headquartered in Lanzhou, China.

Receive News & Ratings for MedAvail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedAvail and related companies with MarketBeat.com's FREE daily email newsletter.